Thematics Asset Management Purchases 63,495 Shares of DexCom, Inc. (NASDAQ:DXCM)

Thematics Asset Management boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 34.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 246,173 shares of the medical device company’s stock after acquiring an additional 63,495 shares during the quarter. Thematics Asset Management owned 0.06% of DexCom worth $16,503,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Jennison Associates LLC lifted its stake in DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after acquiring an additional 6,544,102 shares during the period. Legal & General Group Plc lifted its position in DexCom by 1.7% during the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after purchasing an additional 49,076 shares during the period. Westfield Capital Management Co. LP boosted its holdings in DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in DexCom by 11.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock worth $183,298,000 after purchasing an additional 288,381 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after buying an additional 353,019 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

DXCM has been the subject of several research reports. Leerink Partners reduced their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada cut their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Stifel Nicolaus increased their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Finally, Sanford C. Bernstein upped their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Price Performance

Shares of DexCom stock traded up $5.00 on Tuesday, hitting $77.83. The company’s stock had a trading volume of 6,579,325 shares, compared to its average volume of 3,939,276. The company has a market capitalization of $30.40 billion, a price-to-earnings ratio of 46.60, a price-to-earnings-growth ratio of 2.23 and a beta of 1.17. The firm has a fifty day moving average price of $70.76 and a 200-day moving average price of $88.93. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.